---
title: "Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291956115.md"
description: "Patrick Dolezal of LifeSci Capital raised Neurogene's price target to $65 and reiterated a Buy rating. He cited NGN-401's differentiated clinical profile, strong Phase 1/2 data showing superior milestone gains versus competitors, and the robust Embolden study design. The upgrade reflects improved execution visibility, cash runway, and commercialization preparedness."
datetime: "2026-07-07T15:45:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291956115.md)
  - [en](https://longbridge.com/en/news/291956115.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291956115.md)
---

# Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $65.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Patrick Dolezal has given his Buy rating due to a combination of factors tied to NGN-401’s differentiated clinical profile and the evolving Rett treatment landscape. He views the 12‑month Phase 1/2 data as showing meaningfully higher milestone gains versus a key competitor, reinforcing NGN-401’s potential to secure a substantial share of the market and support long-term value creation.

He also underscores the pivotal Embolden study design, which uses rigorous, blinded assessment of milestone gains against each patient’s own baseline, creating a strong framework to demonstrate clinically meaningful benefit. In addition, he incorporates the recent financing, a lower discount rate as the program advances, and an upward revision of the price target to $65, reflecting improved visibility on execution, cash runway, and the company’s preparedness for eventual commercialization.

According to TipRanks, Dolezal is a 4-star analyst with an average return of 15.2% and a 43.13% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio.

In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $46.00 price target.

### Related Stocks

- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)
- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndrome](https://longbridge.com/en/news/295530994.md)
- [Neurogene Q2 adjusted loss per share misses estimates on employee costs](https://longbridge.com/en/news/295530598.md)
- [Needham Sticks to Their Buy Rating for Establishment Labs Holdings (ESTA)](https://longbridge.com/en/news/295157007.md)
- [Neurogene Q2 FY26 net loss widens to USD 34.49 million](https://longbridge.com/en/news/295529379.md)
- [Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/295146399.md)